Skip to main content

Advertisement

SpringerLink
Log in

ACE and ARB Agents in the Prophylactic Therapy of Migraine—How Effective Are They?

  • Headache (JR Couch, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are antihypertensive agents that can be considered for migraine preventative therapy. Although the exact mechanisms by which ACE inhibitors and ARBs may work for migraine prophylaxis are unknown, there are several plausible hypotheses as to why modulating the activity of the renin angiotensin system could result in migraine prevention. Clinical trials of ACE inhibitors and ARBs provide evidence that they are effective and generally well tolerated when used for migraine prophylaxis. Based upon biologic plausibility, the quality of evidence for efficacy from clinical trials, and recommendations in published guidelines, we consider ACE inhibitors and ARBs as second- or third-line options for migraine prophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lipton RB et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.

    Article  CAS  PubMed  Google Scholar 

  2. Munakata J et al. Economic burden of transformed migraine: results from the American migraine prevalence and prevention (AMPP) study. Headache. 2009;49(4):498–508.

    Article  PubMed  Google Scholar 

  3. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55 Suppl 2:103–22. quiz 123–6.

    Article  PubMed  Google Scholar 

  4. Paterna S et al. Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study. Clin Ter. 1992;141(12):475–81.

    CAS  PubMed  Google Scholar 

  5. Schrader H et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (Lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322(7277):19–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sonbolestan SA et al. Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial. Int J Prev Med. 2013;4(1):72–7. This is a recent randomized placebo-controlled trial of an ACE inhibitor for the preventative treatment of migraine.

    PubMed  PubMed Central  Google Scholar 

  7. Jackson JL et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS ONE. 2015;10(7):e0130733.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Shamliyan TA, Kane RL, and Taylor FR. In Migraine in adults: preventive pharmacologic treatments 2013: Rockville (MD).

  9. Silberstein SD et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology. 2012;78(17):1337–45. These are evidence-based guidelines on the preventative treatment of migraine from the American Academy of Neurology and the American Headache Society.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Pringsheim T et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59. These are evidence-based guidelines on the preventative treatment of migraine from the Canadian Headache Society.

    PubMed  Google Scholar 

  11. Tronvik E et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–9.

    Article  CAS  PubMed  Google Scholar 

  12. Diener HC et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009;29(9):921–7.

    Article  CAS  PubMed  Google Scholar 

  13. Stovner LJ et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2013;34(7):523–32. This is a recent randomized controlled trial of an ARB for the preventative treatment of migraine.

    Article  PubMed  Google Scholar 

  14. Marques-Lopes J et al. Microinjection of angiotensin II in the caudal ventrolateral medulla induces hyperalgesia. Neuroscience. 2009;158(4):1301–10.

    Article  CAS  PubMed  Google Scholar 

  15. Onder G et al. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA). Cephalalgia. 2003;23(9):901–6.

    Article  CAS  PubMed  Google Scholar 

  16. Reuter U et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol. 2002;51(4):507–16.

    Article  CAS  PubMed  Google Scholar 

  17. Lorenzo O et al. Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol. 2002;13(5):1162–71.

    CAS  PubMed  Google Scholar 

  18. Iwai M et al. Attenuation of focal brain ischemia by Telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res. 2008;31(1):161–8.

    Article  CAS  PubMed  Google Scholar 

  19. Horasanli B et al. Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine. Headache. 2013;53(1):161–4.

    Article  PubMed  Google Scholar 

  20. Kowa H et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett. 2005;374(2):129–31.

    Article  CAS  PubMed  Google Scholar 

  21. Paterna S et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000;43(3):133–6.

    Article  CAS  PubMed  Google Scholar 

  22. Lewandowski J et al. The effect of enalapril and Telmisartan on clinical and biochemical indices of sympathetic activity in hypertensive patients. Clin Exp Hypertens. 2008;30(5):423–32.

    Article  CAS  PubMed  Google Scholar 

  23. Tronvik E et al. Involvement of the renin-angiotensin system in migraine. J Hypertens Suppl. 2006;24(1):S139–43. This is a narrative review on how the renin-angiotensin system can play a role in migraine pathophysiology.

    Article  CAS  PubMed  Google Scholar 

  24. Shamliyan TA et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013;28(9):1225–37.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gales BJ et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010;44(2):360–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, AZ, 85054, USA

    Rashmi B. Halker MD, Amaal J. Starling MD, Bert B. Vargas MD & Todd J. Schwedt MD

Authors
  1. Rashmi B. Halker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amaal J. Starling MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bert B. Vargas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Todd J. Schwedt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Todd J. Schwedt MD.

Ethics declarations

Conflict of Interest

Rashmi B. Halker M.D., Amaal J. Starling M.D., and Bert B. Vargas declare that they have no conflict of interest.

Todd J. Schwedt has received personal fees from Supernus, Allergan, and Zogenix.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Headache

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Halker, R.B., Starling, A.J., Vargas, B.B. et al. ACE and ARB Agents in the Prophylactic Therapy of Migraine—How Effective Are They?. Curr Treat Options Neurol 18, 15 (2016). https://doi.org/10.1007/s11940-016-0397-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-016-0397-2

Keywords

Search

Navigation